M. Damian Billy

With over 25 years of experience in finance, private equity, and biotech, I have a strong background in international marketing and a keen interest in revolutionizing the patient care technology process in favor of the individual. As a U.S. Marine Staff Non-Commissioned Officer (NCO), my duties required many responsibilities in various conditions, when leading men. From the first day of stepping on the yellow footprints through any battlefield situation or in life, the mindset of "adjust, adapt, and overcome" applies to any challenges faced. It is the most efficient and effective means of achieving the objective. Our private equity biotech holding company consists of its three associated assets acting as collaborative and complementary patient treatment applications focused on pulmonary diseases. They are (1) a nuclear medicine and molecular imaging (NMMI) technology, (2) a novel wearable therapeutic COPD medical device having derivative disease uses, and (3) a predictive, proactive AI epidemiology platform based on real-world data (RWD) and real-world evidence (RWE). (1) The NMMI technology's efficacy, through prior PH I & II clinical trials, proved to exceed the US standard macroaggregated albumin diagnostic effectiveness by a substantial margin. Due to its function and design, we have the capability to develop multiple disease-related derivatives for COPD, TB, sleep apnea, and others. Our JV deck presentation details its abilities and capacity. (2) The second asset is a novel, wearable COPD medical device with clinical trial results demonstrating an effectiveness of 40% greater than standard COPD treatments. Designed by PhD physiologists, its derivative respiratory disease applications extend to post-TB patient care and sleep apnea. A Class IIa device, it will feature sensors reporting five (5) key performance indicators (KPIs), such as heart rate variability, blood oxygen saturation, and sleep phases associated with sleep apnea. (3) Our predictive AI epidemiology platform will be developed by a former 23-year industry veteran, a PhD informetrics data scientist at the National Institutes of Health. Inclusive of the KPI analysis for therapeutic feedback, the data will generate a diagnostic summarization for MDs, clinicians, research scientists, NGOs, governments, insurance companies, etc.